Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 9:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 277 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Allergic Rhinitis Clear all
Completed Phase 1Phase 2 Interventional Results available

Subcutaneous Immunotherapy for Mouse in Adults

NCT02532179
View directory record Official record
Conditions
Asthma, Perennial Allergic Rhinitis
Interventions
Mouse Allergenic Extract
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Chicago, Illinois • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2018 · Synced Oct 21, 2026, 9:05 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety & Effectiveness of a Nasal Spray to Treat Seasonal Allergies

NCT00719862
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
Placebo nasal spray, 0.15% azelastine hydrochloride Nasal Spray
Drug
Lead sponsor
Meda Pharmaceuticals
Industry
Eligibility
12 Years and older · Female only
Enrollment
481 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
34
States / cities
Huntington Beach, California • Long Beach, California • San Diego, California + 30 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2010 · Synced Oct 21, 2026, 9:05 AM EDT
Terminated Not applicable Interventional

Oxymetazoline Hydrochloride in Combination With Nasal Glucocorticosteroid for Perennial Allergic and Non-allergic Rhinitis in Subjects With Persistent Nasal Congestion

NCT00584662
View directory record Official record
Conditions
Chronic Rhinitis
Interventions
Oxymetazoline Hydrochloride
Drug
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jun 28, 2012 · Synced Oct 21, 2026, 9:05 AM EDT
Completed Phase 2 Interventional

Dose Selection Study of Efficacy and Safety of Different Doses of Grass MATA MPL and Grass MATA Using mEECs™

NCT02582073
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
Placebo (0.5ml), Placebo (1.0ml), Grass MATA MPL (0.5ml) 5100SU, Grass MATA MPL (1.0ml) 10200SU, Grass MATA MPL (1.0ml) 18200SU, Grass MATA (0.5ml) 5100SU
Biological
Lead sponsor
Allergy Therapeutics
Industry
Eligibility
18 Years to 50 Years
Enrollment
265 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Neptune City, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 29, 2021 · Synced Oct 21, 2026, 9:05 AM EDT
Completed Phase 3 Interventional

A Study To Evaluate The Efficacy And Safety Of A Once-Daily Investigational Nasal Spray In Adults And Adolescents With Perennial Allergic Rhinitis (PAR).

NCT00103454
View directory record Official record
Conditions
Rhinitis, Allergic, Perennial
Interventions
GW685698X
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
43
States / cities
Little Rock, Arkansas • Los Angeles, California • Mission Viejo, California + 37 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2016 · Synced Oct 21, 2026, 9:05 AM EDT
Withdrawn Phase 3 Interventional

Topical Allstate and Nasal Allergen Challenge

NCT01231724
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
Allstate Nasal Spray, Placebo Nasal Spray
Device
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 55 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 3, 2013 · Synced Oct 21, 2026, 9:05 AM EDT
Completed Phase 3 Interventional Results available

Efficacy Study of Sublingual Immunotherapy to Treat Ragweed Allergies

NCT00599872
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
Standardized Ragweed Allergenic Extract, Placebo
Biological
Lead sponsor
Greer Laboratories
Industry
Eligibility
18 Years to 50 Years
Enrollment
430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
30
States / cities
Normal, Illinois • Evansville, Indiana • Iowa City, Iowa + 23 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2015 · Synced Oct 21, 2026, 9:05 AM EDT
Completed Phase 3 Interventional

Efficacy, Safety, and Tolerability Study of ACT-129968 in Patients With Seasonal Allergic Rhinitis

NCT01484119
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
ACT-129968, Placebo, Cetirizine
Drug
Lead sponsor
Idorsia Pharmaceuticals Ltd.
Industry
Eligibility
12 Years to 76 Years
Enrollment
630 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
7
States / cities
Austin, Texas • Kerrville, Texas • New Braunfels, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2018 · Synced Oct 21, 2026, 9:05 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Orotic Acid Derivatives With or Without Glutathione on Allergic Rhinitis

NCT00227058
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
Orotic acid and Glutathione-(Nutritional Supplements)
Drug
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
18 Years to 64 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Jan 26, 2007 · Synced Oct 21, 2026, 9:05 AM EDT
Completed Phase 3 Interventional

Investigation of Potential Additive Inhibitory Effects on HPA-Axis of Ciclesonide Nasal Spray When Administered Concomitantly With Orally Inhaled Beclomethasone Dipropionate (HFA-BDP) in Patients With Perennial Allergic Rhinitis (PAR) (BY9010/M1-408)

NCT00659048
View directory record Official record
Conditions
Rhinitis, Allergic, Perennial
Interventions
Ciclesonide, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 60 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 1, 2016 · Synced Oct 21, 2026, 9:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Tolerability of XmAb®7195 in Adult Healthy Volunteers and Adult Subjects With a History of Allergic Rhinitis and/or Allergic Conjunctivitis and/or Atopic Dermatitis

NCT02148744
View directory record Official record
Conditions
Allergic Rhinitis, Allergic Conjunctivitis, Atopic Dermatitis
Interventions
XmAb7195, Placebo
Biological
Lead sponsor
Xencor, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 24, 2017 · Synced Oct 21, 2026, 9:05 AM EDT
Completed Phase 3 Interventional

Safety and Tolerability of Ciclesonide Nasal Spray in Patients With Perennial Allergic Rhinitis (2-5 Years Old) (BY9010/M1-416)

NCT00261287
View directory record Official record
Conditions
Hay Fever, Perennial Allergic Rhinitis
Interventions
Ciclesonide
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
2 Years to 5 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
3
States / cities
Long Beach, California • Normal, Illinois • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 30, 2016 · Synced Oct 21, 2026, 9:05 AM EDT
Not listed Phase 1 Interventional

Safety of Lymph Node Injection for Allergen Immunotherapy

NCT01982474
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
Grass pollen extract, Placebo injection
Biological · Other
Lead sponsor
Amber Patterson
Other
Eligibility
15 Years to 24 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 9, 2016 · Synced Oct 21, 2026, 9:05 AM EDT
Completed No phase listed Observational

Pilot Study of Allergy Immunotherapy and Prevention of Viral Respiratory Infections

NCT00405899
View directory record Official record
Conditions
Allergy, Seasonal Allergic Rhinitis, Perennial Allergic Rhinitis
Interventions
Not listed
Lead sponsor
West Penn Allegheny Health System
Other
Eligibility
6 Years to 18 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 31, 2010 · Synced Oct 21, 2026, 9:05 AM EDT
Completed Phase 3 Interventional Results available

Once-Daily Investigational Nasal Spray In Adults And Adolescents With Perennial Allergic Rhinitis (PAR)

NCT00289198
View directory record Official record
Conditions
Rhinitis, Allergic, Perennial
Interventions
FF, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
8
States / cities
San Diego, California • Baltimore, Maryland • Wheaton, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2018 · Synced Oct 21, 2026, 9:05 AM EDT
Completed Phase 3 Interventional Results available

A Safety and Efficacy Study of Ciclesonide Nasal Aerosol in Subjects 6-11 Years With Seasonal Allergic Rhinitis (SAR)

NCT01458275
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
Ciclesonide nasal aerosol 37 mcg, ciclesonide nasal aerosol 74 mcg, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
6 Years to 11 Years
Enrollment
847 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
66
States / cities
Little Rock, Arkansas • Baldwin Park, California • Costa Mesa, California + 49 more
Source: ClinicalTrials.gov public record
Updated May 15, 2014 · Synced Oct 21, 2026, 9:05 AM EDT
Terminated Phase 1 Interventional

Study Evaluating Safety of Ragweed Mix Given by Intralymphatic Node Injections

NCT03038971
View directory record Official record
Conditions
Allergic Conjunctivitis, Allergic Rhinitis
Interventions
Dose Level 1, Dose Level 2, Placebo
Biological
Lead sponsor
Woodmont Pharmaceuticals, Inc.
Industry
Eligibility
16 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 26, 2018 · Synced Oct 21, 2026, 9:05 AM EDT
Terminated Phase 3 Interventional Results available

Clinical Equivalence Study of Fluticasone Propionate Nasal Spray, 50 mcg/Actuation vs. Flonase in Allergic Rhinitis Patients

NCT02246920
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
Fluticasone propionate, Flonase®, Placebo
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
12 Years and older
Enrollment
1,474 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 8, 2023 · Synced Oct 21, 2026, 9:05 AM EDT
Terminated Phase 2 Interventional

Exploratory Study for Allergy Relief Onset

NCT02722083
View directory record Official record
Conditions
Rhinitis, Allergic
Interventions
Chlorpheniramine maleate (BAY X002134), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Germantown, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 12, 2018 · Synced Oct 21, 2026, 9:05 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of GSP 301 Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (SAR)

NCT02870205
View directory record Official record
Conditions
Seasonal Allergic Rhinitis (SAR)
Interventions
GSP 301 NS, GOM-NS, GMM-2 NS, GSP 301 placebo NS
Drug
Lead sponsor
Glenmark Specialty S.A.
Industry
Eligibility
12 Years and older
Enrollment
1,176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
43
States / cities
Mission Viejo, California • Orange, California • San Diego, California + 33 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2018 · Synced Oct 21, 2026, 9:05 AM EDT
Completed Phase 3 Interventional Results available

Study of an Investigational Nasal Aerosol or Placebo Nasal Aerosol in Children (Ages 6-11) With Seasonal Allergies

NCT01307319
View directory record Official record
Conditions
Seasonal Allergic Rhinitis, SAR
Interventions
BDP HFA, Placebo nasal aerosol
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
6 Years to 11 Years
Enrollment
715 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
45
States / cities
Oxford, Alabama • Bell, California • Costa Mesa, California + 40 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2015 · Synced Oct 21, 2026, 9:05 AM EDT
Completed No phase listed Observational

An Observational Study to Evaluate The Relationship of Nasal Mucus Properties and Symptoms

NCT01553110
View directory record Official record
Conditions
Acute Rhinosinusitis, Allergic Rhinitis
Interventions
Not listed
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
12 Years to 100 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 25, 2019 · Synced Oct 21, 2026, 9:05 AM EDT
Withdrawn Phase 4 Interventional

A Pilot Investigation of Ciclesonide When Administered as a Hypotonic Versus an Isotonic Formulation of Ciclesonide Nasal Spray

NCT00793858
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
placebo, isotonic ciclesonide, hypotonic ciclesonide
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 7, 2013 · Synced Oct 21, 2026, 9:05 AM EDT
Withdrawn Phase 2Phase 3 Interventional

Efficacy and Safety of Grass-SPIRE Registration Study

NCT02795273
View directory record Official record
Conditions
Rhinitis, Conjunctivitis
Interventions
Grass-SPIRE, Placebo
Drug
Lead sponsor
Circassia Limited
Industry
Eligibility
12 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2016
U.S. locations
2
States / cities
Canton, Ohio • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 23, 2016 · Synced Oct 21, 2026, 9:05 AM EDT